Company Overview - Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for patients with solid tumors [3] - The company's lead program, ficerafusp alfa, is a first-in-class bifunctional antibody aimed at enhancing tumor penetration by addressing challenges in the tumor microenvironment [3] Product Details - Ficerafusp alfa combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) [3] - This targeted mechanism aims to reverse the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling, facilitating deeper and more durable responses in treatment [3] - Ficerafusp alfa is currently being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [3] Upcoming Events - Claire Mazumdar, PhD, MBA, the CEO of Bicara Therapeutics, will present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026, at 11:15 a.m. PT [1] - A live webcast of the presentation will be available on the Investor Relations section of Bicara's website, with a replay accessible after the event [2]
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12